Terms: = Prostate cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Prognosis
3 results:
1. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract] [Full Text] [Related]
2. TMPRSS2 Met160Val polymorphism: significant association with sporadic prostate cancer, but not with latent prostate cancer in Japanese men.
Maekawa S; Suzuki M; Arai T; Suzuki M; Kato M; Morikawa T; Kasuya Y; Kume H; Kitamura T; Homma Y
Int J Urol; 2014 Dec; 21(12):1234-8. PubMed ID: 25040002
[TBL] [Abstract] [Full Text] [Related]
3. Pathological significance and predictive value for biochemical recurrence of c-fes expression in prostate cancer.
Miyata Y; Watanabe S; Matsuo T; Hayashi T; Sakai H; Xuan JW; Greer PA; Kanda S
Prostate; 2012 Feb; 72(2):201-8. PubMed ID: 21563194
[TBL] [Abstract] [Full Text] [Related]
